SuspendedPhase 4ketamine

IM Ketamine vs Midazolam for Suicidal ER Patients

Sponsored by New York State Psychiatric Institute

NCT ID
NCT04640636
Target Enrollment
90 participants
Start Date
2021-02-09
Est. Completion
2028-03

About This Study

Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide. There is no approved treatment for rapid relief of suicidal thoughts although clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, sub-anesthetic ketamine. We propose a clinical trial of intramuscular ketamine in depressed ED patients with high-risk suicidality, which if successful would support a novel, easy-to-use, scalable intervention for busy emergency clinicians to implement. NOTE: The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research began in June, 2023. The U.S. Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) issued an FWA restriction on NYSPI research that also included a pause of human subjects research as of June 23, 2023. Non-HHS Studies: The IO in concurrence with the IRB paused human subjects research on June 12, 2023. Therefore, the NYSPI site is not enrolling at this time.

Conditions Studied

Depression, UnipolarDepression, BipolarSuicidal Ideation

Interventions

  • Ketamine hydrochloride injection
  • Midazolam injection

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* DSM5 unipolar or bipolar (I, II, or Unspecified) major depressive episode
* Presenting to emergency department and assessed by psychiatrist staff as needing inpatient treatment due to suicidality
* Participant agrees to voluntary inpatient psychiatric admission
* Beck Scale for Suicidal Ideation score of 4 or higher

Exclusion Criteria:

* Substance use disorder in past 2 weeks
* Current psychosis or mania
* Intellectual disability
* Inadequate understanding of English and/or lack of capacity for informed consent
* Pregnancy or lactation
* Medical contraindication to ketamine or midazolam
* Unstable medical or neurological illness such as uncontrolled hypertension, significant cardiac arrhythmia, unstable cerebrovascular disease. Chronic, stable medical conditions such as controlled hypertension or diabetes will not be excluded.

Study Locations (1)

Comprehensive Psychiatric Emergency Department of Columbia University Medical Center
New York, New York, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

IM Ketamine vs Midazolam for Suicidal ER Patients | Huxley